---
schema_version: "secwatch.filing_event.v1"
accession: "0001564590-21-053950"
form_type: "8-K"
ticker: "VKTX"
cik: "0001607678"
company_name: "Viking Therapeutics, Inc."
filed_at: "2021-11-03T23:59:59+00:00"
generated_at: "2026-06-28T14:04:15.895675+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Viking Q3 net loss $0.17/share; cash $216M; VK2809 VOYAGE trial ongoing

## Summary
- Net loss of $13.2M ($0.17 per share) in Q3 2021 vs $9.3M ($0.13) in Q3 2020.
- Cash, cash equivalents and short-term investments of $216.1M as of Sept 30, 2021 ($248.4M at Dec 31, 2020).
- Phase 2b VOYAGE trial for VK2809 (NASH) enrolling; initial data expected in 2022.
- Phase 1b trial of VK0214 in X-ALD (AMN) underway; top-line results expected in 2022.
- Preclinical dual GLP-1/GIP agonists showed up to 27% body weight reduction; clinical development planned.

## SEC filing metadata
- accession: 0001564590-21-053950
- form_type: 8-K
- ticker: VKTX
- cik: 0001607678
- company_name: Viking Therapeutics, Inc.
- filed_at: 2021-11-03T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1607678/000156459021053950/0001564590-21-053950-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1607678/000156459021053950/vktx-8k_20211103.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001564590-21-053950
- JSON: https://secwatch.observer/filing/0001564590-21-053950.json
- Plain text: https://secwatch.observer/filing/0001564590-21-053950.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.